Delivery Order SPE2DB20D9354-SPE2DB25FX7X3
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $10,375.53 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Nuplazid 34 mg capsules in 30-count units. The award, issued on July 21, 2025, with an ultimate completion date of August 11, 2025, carries a firm fixed-price contract structure with no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract valued at $10,093.50 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, which has an ultimate completion date of December 9, 2024, is for the delivery of Nuplazid 34 mg capsules. DMS Pharmaceutical Group holds a larger Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at $499,999,999 and...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $10,375.53 to DMS Pharmaceutical Group Inc. for the supply of Nuplazid 34 mg capsules (30-count units) on July 30, 2025, with an ultimate completion date of August 20, 2025. This firm fixed-price delivery order was issued without a set-aside designation and is being performed at the contractor's location in Park Ridge, Illinois. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, is the prime...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, has been awarded a delivery order valued at $10,375.53 for 30 Nuplazid 34 mg capsules by the Defense Logistics Agency's Medical Supply Chain on August 7, 2025. This firm fixed-price delivery order, with an ultimate completion date of August 28, 2025, represents a continuation of pharmaceutical supply services to the Department of Defense healthcare system. The contract carries...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,458.51 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of NUPLAZID 34 mg capsules (30-count units). This firm fixed-price delivery order, issued on August 7, 2025, with completion targeted for August 28, 2025, represents a discrete fulfillment under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA valued at...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $10,093.50 contract is for the supply of Nuplazid 34 mg capsules with a performance period through May 28, 2024. This delivery order is placed under DMS Pharmaceutical Group's $499,999,999 single-award Indefinite Delivery Contract (IDC) with the DLA, which allows the agency to issue firm...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract worth $3,458.51 to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract is for the delivery of Nuplazid 34 mg capsules and has a performance period through May 12, 2025. DMS Pharmaceutical Group holds a larger Indefinite Delivery Contract (IDC) worth up to $499,999,999 with the DLA under the SPE2DB program, which enables the agency to issue delivery orders...
- The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract worth $10,093.50 to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract is for the delivery of 4,566,210,999 units of the pharmaceutical product Nuplazid 34 mg capsule 30s. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at $499,999,999 that DMS Pharmaceutical Group holds with the DLA under the SPE2DB program. The IDC covers a...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $6,729 contract is for the delivery of Nuplazid 34 mg capsules by January 3, 2025. DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the agency to issue firm fixed-price delivery orders for a wide range...
- The U.S. Department of Defense Medical Supply Chain awarded a delivery order valued at $20,751.06 to DMS Pharmaceutical Group Inc. for 30 capsules of Nuplazid 34 mg on August 18, 2025, with an ultimate completion date of September 9, 2025. This firm fixed-price delivery order was issued without a set-aside designation and is being performed in Park Ridge, Illinois. Nuplazid (pimavanserin) is an atypical antipsychotic used to treat psychosis associated with Parkinson's disease, and this order...
- SPE2DB20D9354Indefinite Delivery Contract
- SPE2DB20D9354-SPE2DB25FX7X3Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $10,375.53 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, on August 20, 2025. The contract covers the supply of Nuplazid 34 mg capsules in quantities of 30, with a firm fixed-price structure and an ultimate completion date of September 11, 2025. This delivery order was issued without a set-aside designation, allowing the vendor to compete on an unrestricted basis despite its small business status. This award is issued under DMS Pharmaceutical Group's larger single-award Indefinite Delivery Contract with the DLA valued at $499,999,999 through November 2026, which authorizes the agency to issue delivery orders for a comprehensive range of pharmaceutical products supporting military health facilities worldwide. The company has established itself as a critical supplier in the federal pharmaceutical supply chain, with a robust portfolio of contract awards covering branded and generic prescription drugs, biologics, and specialty medications. Nuplazid (pimavanserin), an atypical antipsychotic used primarily in treating psychosis associated with Parkinson's disease, represents one of many specialized pharmaceutical products DMS Pharmaceutical supplies to Department of Defense healthcare sites.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $10.4k | 8/20/25 |